Effects of octreotide treatment on restenosis after coronary angioplasty: Results of the VERAS study

Circulation

Volumn 96, Issue 5, 1997, Pages 1482-1487

  Von Essen, Rainer ^a   Ostermaier, Ralf ^a   Grube, Eberhard ^c   Mäurer, Wolfgang ^c   Tebbe, Ulrich ^c   Erbel, Raimund ^c   Roth, Michael ^a   Oel, Werner ^a   Brom, Joachim ^b   Weidinger, Gottfried ^b  

^a Klinik Augustinum Munchen   (Germany)

^b Sandoz   (Germany)

^c Stiftsklinik Augustinum ^*

Author keywords

Angioplasty; Octreotide; Restenosis

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0030776361     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.5.1482     Document Type: Article

References (33)

1. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JHC, ten Katen HJ, van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361-371.
2. Liu MW, Roubin GS, King SB III. Restenosis after coronary angioplasty: potential biologic determinants and role of intimai hyperplasia. Circulation. 1989;79:1374-1387.
3. Jackson CL, Schwartz SM. Pharmacology of smooth muscle cell replication. Hypertension. 1992;20:713-736.
4. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(suppl III):III-47-III-52.
5. Epstein SE, Speir E, Unger EF, Guzman RJ, Finkel T. The basis of molecular strategies for treating coronary restenosis after angioplasty. J Am Coll Cardiol. 1994;23:1278-1288.
6. Nikol S, Huehns TY, Höfling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis. 1996;123:17-31.
7. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem. 1988;57:443-478.
8. Cohen P. Signal integration at the level of protein kinases, protein phosphatases and their substrates. Trends Biochem Sci. 1992;17: 408-413.
9. Pallen CJ, Tan YH, Guy GR. Protein phosphatases in cell signalling. Curr Opin Cell Biol. 1992;4:1000-1007.
10. Lau KH, Baylink DJ. Phosphotyrosyl protein phosphatases: potential regulators of cell proliferation and differentiation. Crit Rev Oncol. 1993;4:451-471.
11. Colas B, Cambillau C, Buscail L, Zeggari M, Esteve JP, Lautre V, Thomas F, Vaysse N, Susini C. Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells. Eur J Biochem. 1992;207:1017-1024.
12. Buscail L, Delesque N, Esteve J-P, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, Vaysse N, Susini C. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA. 1994;91:2315-2319.
13. Ezzat S, Ren S-G, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab. 1992;75:1459-1463.
14. Wolthers T, Grøfte T, Flyvbjerg A, Frystyk J, Vilstrup H, Ørskov H, Foegh M. Lanreotide, a somatostatin analogue, dose dependently stimulates insulin-like growth factor binding protein I. J Clin Endocrinol Metab. 1994;78:141-144.
15. Lundergan C, Foegh ML, Vargas R, Eufemio M, Bormes GW, Kot PA, Ramwell PW. Inhibition of myointimal proliferation of the rat carotid artery by the peptides, angiopeptin and BIM 23034. Atherosclerosis. 1989;80:49-55.
16. Santoian EC, Schneider JE, Gravanis MB, Foegh M, Tarazona N, Cipolla GD, King SB III. Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries. Circulation. 1993;88: 11-14.
17. Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells: a potential treatment for restenosis? Circulation. 1994;89:1511-1517.
18. Yumi K, Fagin JA, Dimayuga P, Yano J, Forrester JS, Cercek B. Somatostatin analogue octreotide decreases arterial IGF-1 gene expression and neointimal thickening after injury. Clin Res. 1994; 42:15A. Abstract.
19. Yamashita M, Dimayuga P, Zhu J, Yano J, Kaul S, Shah PK, Regnstrom J, Nilsson J, Cercek B. Effect of somatostatin analog octreotide on AP-1 and nuclear factor-κB activation and cell proliferation after balloon injury. J Invest Med. 1996;44(suppl 1):101A. Abstract.
20. Beier J, Oswald H, Fleck E. Edge detection for coronary angiograms: error correction and impact of derivatives. IEEE Comp Soc Press. 1992;513-516.
21. Bairati I, Roy L, Meyer F. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation. 1992;85:950-956.
22. Herrman J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the holy grail? Drugs. 1993;46:18-52(pt I), 249-262(pt II).
23. Eriksen UH, Amtorp O, Bagger JP, Emanuelsson H, Foegh M, Henningsen P, Saunamäki K, Schaeffer M, Thayssen P, Orskov H, Kuntz RE, Popma JJ. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J. 1995;130:1-8.
24. Emanuelsson H, Beatt KJ, Bagger J-P, Balcon R, Heikkilä J, Piessens J, Schaeffer M, Suryapranata H, Foegh M, for the European Angiopeptin Study Group. Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis. Circulation. 1995;91: 1689-1696.
25. Kent KM, Williams DO, Cassagneau B, Broderick T, Chapekis A, Simpfen-dorfer C, Cote G, Bates E, Tauscher G, Kuntz RE, Popma JJ, Foegh M. Double blind, controlled trial of the effect of angiopeptin on coronary restenosis following balloon angioplasty. Circulation. 1993;88(suppl I):I-506, Abstract.
26. Lamberts SW, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334:246-254.
27. Glagov S. Intimai hyperplasia, vascular modeling, and the restenosis problem. Circulation. 1994;89:2888-2891.
28. Schwartz SM. How vessels narrow. Z Kardiol. 1995;84(suppl 4):129-135.
29. Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, Ferrara N, Symes JF, Isner JM. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimai hyperplasia in balloon-injured rat carotid artery. Circulation. 1995;91:2793-2801.
30. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet. 1996;347:305-307.
31. Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J. 1995; 130(suppl):666-672.
32. Ferguson JJ III. EPILOG and CAPTURE trials halted because of positive interim results. Circulation. 1996;93:637.
33. Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, Fontanelli A, Monici Preti PA, Repetto S, De Servi S, Varani E for the STARC Investigators. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Circulation. 1994;90: 2710-2715.